Larimar Therapeutics Inc (LRMR)

07:22 AM

Larimar Therapeutics Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView

07:22 AM

Mar 08, 2025

Larimar Therapeutics to Present at Leerink Partners Global Healthcare Conference - MSN

Mar 08, 2025

Mar 03, 2025

Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference - GlobeNewswire

Mar 03, 2025

Mar 03, 2025

Will Larimar's Rare Disease Pipeline Updates Move the Needle? Key Investor Conference Coming - StockTitan

Mar 03, 2025

Feb 26, 2025

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World

Feb 26, 2025

Feb 25, 2025

Financial Metrics Exploration: Understanding Larimar Therapeutics Inc (LRMR) Through Ratios - The Dwinnex

Feb 25, 2025

Feb 14, 2025

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Holdings Boosted by SG Americas Securities LLC - Defense World

Feb 14, 2025

Feb 12, 2025

Insiders Re-Evaluate Their US$522.0k Stock Purchase As Larimar Therapeutics Falls To US$215m - Simply Wall St

Feb 12, 2025

Feb 05, 2025

BlackRock, Inc. Increases Stake in Larimar Therapeutics Inc - GuruFocus.com

Feb 05, 2025

Feb 05, 2025

Insider’s View: Deciphering Larimar Therapeutics Inc (LRMR)’s Financial Health Through Ratios - The Dwinnex

Feb 05, 2025

Feb 05, 2025

Larimar Therapeutics Inc (LRMR)’s stock chart: A technical perspective - US Post News

Feb 05, 2025

Feb 04, 2025

Analysts Set Larimar Therapeutics, Inc. (NASDAQ:LRMR) PT at $20.13 - MarketBeat

Feb 04, 2025

Feb 02, 2025

Larimar Therapeutics (NASDAQ:LRMR) Coverage Initiated at Truist Financial - MarketBeat

Feb 02, 2025

Feb 02, 2025

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Shares Bought by JPMorgan Chase & Co. - Defense World

Feb 02, 2025

Feb 01, 2025

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of “Buy” from Analysts - Defense World

Feb 01, 2025

Jan 31, 2025

Truist Financial Initiates Coverage on Larimar Therapeutics (NASDAQ:LRMR) - Defense World

Jan 31, 2025

Jan 30, 2025

Larimar started at buy by Truist on Friedreich's ataxia drug - MSN

Jan 30, 2025

Jan 29, 2025

Truist Initiates Larimar Therapeutics at Buy With $18 Price Target -January 29, 2025 at 06:37 am EST - Marketscreener.com

Jan 29, 2025

Jan 29, 2025

This MicroStrategy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Jan 29, 2025

Jan 28, 2025

Larimar Therapeutics awards key executives performance-based stock By Investing.com - Investing.com Australia

Jan 28, 2025

Jan 28, 2025

Larimar Therapeutics Aligns Executive Incentives with Milestones - MSN

Jan 28, 2025

Jan 27, 2025

Larimar Therapeutics awards key executives performance-based stock - MSN

Jan 27, 2025

Jan 27, 2025

Larimar Therapeutics' SWOT analysis: stock potential hinges on FA treatment - MSN

Jan 27, 2025

Jan 26, 2025

JMP Securities maintains $21 target on Larimar Therapeutics stock - MSN

Jan 26, 2025

Jan 26, 2025

Larimar Therapeutics (NASDAQ:LRMR) Earns “Buy” Rating from HC Wainwright - Defense World

Jan 26, 2025

Jan 25, 2025

Larimar Therapeutics Initiates Dosing in Pediatric Study for Friedreich’s Ataxia - MSN

Jan 25, 2025

Jan 25, 2025

Larimar Therapeutics' SWOT analysis: stock potential hinges on FA treatment By Investing.com - Investing.com Australia

Jan 25, 2025

Jan 25, 2025

Assenagon Asset Management S.A. Sells 6,488 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World

Jan 25, 2025

Jan 25, 2025

Larimar Therapeutics’ SWOT analysis: stock potential hinges on FA treatment By Investing.com - Investing.com Nigeria

Jan 25, 2025

Jan 24, 2025

Larimar Therapeutics' (LRMR) Buy Rating Reiterated at HC Wainwright - MarketBeat

Jan 24, 2025

Jan 24, 2025

Larimar Therapeutics, Inc. Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia - Marketscreener.com

Jan 24, 2025

Jan 23, 2025

Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia - The Manila Times

Jan 23, 2025

Jan 23, 2025

Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia - Business Upturn

Jan 23, 2025

Jan 23, 2025

Larimar Therapeutics Announces Dosing of Adolescents in - GlobeNewswire

Jan 23, 2025

Jan 20, 2025

Larimar Therapeutics Shares Promising Data on Nomlabofusp at Ataxia Research Congress - MSN

Jan 20, 2025

Jan 19, 2025

Barclays PLC Buys 45,781 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World

Jan 19, 2025

Jan 08, 2025

JANUS HENDERSON GROUP PLC Acquires Additional Shares in Larimar Therapeutics Inc - GuruFocus.com

Jan 08, 2025

Jan 07, 2025

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of “Buy” from Analysts - Defense World

Jan 07, 2025

Jan 07, 2025

Brokerages Set Larimar Therapeutics, Inc. (NASDAQ:LRMR) PT at $20.43 - MarketBeat

Jan 07, 2025

Jan 06, 2025

Bullish Larimar Therapeutics Insiders Loaded Up On US$522.0k Of Stock - Yahoo Finance

Jan 06, 2025

Jan 05, 2025

Geode Capital Management LLC Decreases Stake in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World

Jan 05, 2025

Jan 05, 2025

Geode Capital Management LLC Has $5.90 Million Stock Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - MarketBeat

Jan 05, 2025